Back to top

5 Stocks Rocketing to New Highs

Read MoreHide Full Article

 

After spending most of the session in the red, it looks like equities are about to push themselves into the green today. That’s great news for a market that seems to be shaking off a relatively weak earnings season well. Looks to me like a weaker euro is helping to move things along.

Regardless of why the market is going up, sometimes it can feel like the market is passing you by. For one reason or another you’ve found yourself with more money on the sidelines than you’d like to admit. When the market keeps pushing higher like this, it’s easy to believe that you’ve missed the boat.

Click “FOLLOW THE AUTHOR” for free stock picks!!! And Twitter @bartosiastics

Let’s face it though, you’re never going to catch the perfect day to buy the market just like you’re never going to find the perfect stock to buy. But who said you need to? You probably don’t drive the perfect car, or live in the perfect house. The stock market isn’t about making the perfect trade at the perfect time. It’s about making enough good trades to outnumber your bad trades over time.

Here I’ve dipped back into the well of the Zacks Rank to find some good stock trades we can make today. These stocks are Zacks Rank #1 (Strong Buy) and Zacks Rank #2 (Buy) stocks that have Momentum Style Scores of “A” or “B” that are breaking out to new 52-week highs. This gives you the triple threat of stock success. You have stocks that are breaking out on the charts, have analysts in increasingly bullish moods, and are showing big time signs of earnings momentum.

Click “FOLLOW THE AUTHOR” for free stock picks!!! And Twitter @bartosiastics

I’ve been using the same formula to come up with winning ideas week in and week out. Today I’ve got five fantastic stock ideas to buy.

Angie’s List (ANGI - Free Report)

Angie’s List, Inc. operates a local services marketplace and consumer review site in the United States. The company provides marketplace to research, shop for, and purchase local services for home, health, and automotive service needs. It also allows its consumers to rate and review service providers in 253 markets. In addition, the company provides advertising services to service providers through its monthly publication and call center; and on its Website, as well as through mobile applications.

I’m kicking myself here with Angie’s List because I passed on pulling the trigger with the stock just below $7. It was on my radar and I came up with a couple reasons why not. Well this time I’m not going to let that voice in my head convince me otherwise. Support lies down at $7.20 with shares above the February high of $7.80. The 20-day moving average sits down at $6.87, confirming the bullish intermediate term trend.

Click “FOLLOW THE AUTHOR” for free stock picks!!! And Twitter @bartosiastics

athenahealth (ATHN - Free Report)

athenahealth, Inc., together with its subsidiaries, operates as a business services company that provides ongoing billing, clinical-related, and other related services to medical group practices and health systems in the United States. The company provides services through athenaNet, a cloud-based platform. Its services include athenaCollector for revenue cycle management and medical billing; athenaClinicals for electronic health record management; athenaCommunicator for patient engagement and communication; and athenaCoordinator for care coordination, population health, and financial and quality management.

A big earnings report helped catapult shares of athenahealth from $135 all the way to $165. Shares came down in the three days following earnings, found support at $145 and then have been making the break higher again. The fresh 52-week high yesterday could mean ATHN is on the verge of another probe higher as the market searches for a new fair value.

Click “FOLLOW THE AUTHOR” for free stock picks!!! And Twitter @bartosiastics

Cytokinetics (CYTK - Free Report)

Cytokinetics, Incorporated, a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. It is involved in developing Tirasemtiv, a fast skeletal troponin activator that is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis; CK-2127107 that is in Phase I for the treatment of spinal muscle atrophy; and Omecamtiv mecarbil, which is in Phase II clinical trials for the potential treatment of heart failure. 

CYTK has gone nuclear after finding support at a thick band of volume just above $6.50 in mid-October. From there, the rally has nearly doubled shares has volumes have also increased. The stock traded 3 million shares during its breakout and has been averaging over 750k the last several trading days.

Click “FOLLOW THE AUTHOR” for free stock picks!!! And Twitter @bartosiastics

MeetMe (MEET - Free Report)

MeetMe, Inc. owns and operates a social network for meeting new people on the Web and on mobile platforms in the United States. The company operates MeetMe.com that provides users with access to various multilingual menu of resources, which promote social interaction, information sharing, and other topics of interest. 

This stock may just have found itself on the map. Shares have moved from $1.50 to popping above $3 in just over a month. The 20-day moving average sits down at $2.38, providing the downside support on the current bullish trend. The CCI is just below 84, indicating the stock is not too overbought even at current levels. Volumes have increased dramatically as of late.

Click “FOLLOW THE AUTHOR” for free stock picks!!! And Twitter @bartosiastics

Visteon (VC - Free Report)

Visteon Corporation designs, engineers, and manufactures products for original equipment vehicle manufacturers worldwide. It operates in three segments: Climate, Electronics, and Other. The company also sells its products for use as aftermarket and service parts to automotive original equipment manufacturers and others for resale through independent distribution networks. 

Visteon has been irreverent of the market trend over the last year. The recent rally started in late August with shares down below $96. From there the stock has gone virtually straight up, culminating in a meteoric rise since the last earnings report that has shares up near $117 now.

Click “FOLLOW THE AUTHOR” for free stock picks!!! And Twitter @bartosiastics

Bottom Line

You don’t have to feel bad for missing the market move higher. It’s impossible to find the perfect time to buy the perfect stock. Just put the odds in your favor by buying Zacks Rank #1 (Strong Buy) and Zacks Rank #2 (Buy) stocks that are showing strong momentum and are breaking out to new highs. I’ve been making money doing this all year and I’m not going to stop any time soon.

Be sure to click FOLLOW THE AUTHOR above to stay on top of all the hot momentum stocks at Zacks.com. David Bartosiak is the Momentum Stock Strategist with Zacks, editor of the Momentum Trader and Home Run Investor, and host of “Trending Stocks”

 



More from Zacks Investment Ideas

You May Like